World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
47
Citations
13039
World Ranking
4474
National Ranking
48

Eyad Elkord publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Eyad Elkord sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 151 publications — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Eyad Elkord D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Eyad Elkord sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 47 D-Index — 9th percentile

9% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Eyad Elkord is affiliated with Xi'an Jiaotong-Liverpool University in China and has a significant body of research spanning medicine, immunology, and molecular biology. Their work focuses primarily on immune mechanisms and cancer, with particular emphasis on immunotherapy and biomarker discovery.

The main fields of study in Elkord's research include:

  • Medicine
  • Immunology and Microbiology
  • Biochemistry, Genetics and Molecular Biology

Within these broader fields, subfields of study cover:

  • Immunology
  • Oncology
  • Molecular Biology
  • Cancer Research
  • Infectious Diseases

Elkord's research extensively addresses topics such as:

  • Cancer Immunotherapy and Biomarkers
  • Immune Cell Function and Interaction
  • Immune cells in cancer
  • COVID-19 Clinical Research Studies
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • MicroRNA in disease regulation

Frequent publication venues include:

  • Vaccines
  • Cancer Immunology Immunotherapy
  • Frontiers in Immunology
  • International Immunopharmacology
  • Clinical Immunology

Some of the recent papers by Elkord are:

  • FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets, 2020, Cancer Letters
  • T-cell responses and therapies against SARS-CoV-2 infection, 2020, Immunology
  • Single-Cell Transcriptome Analysis Highlights a Role for Neutrophils and Inflammatory Macrophages in the Pathogenesis of Severe COVID-19, 2020, Cells
  • Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer, 2020, Cancer Immunology Immunotherapy
  • Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression, 2020, Frontiers in Immunology

Elkord has collaborated frequently with multiple coauthors, including:

  • Salman M. Toor
  • Varun Sasidharan Nair
  • Reem Saleh
  • Khaled Murshed
  • Mohamed Abu Nada

Best Publications

  • Immune checkpoint inhibitors: recent progress and potential biomarkers.

    Pramod Darvin;Salman M. Toor;Varun Sasidharan Nair;Eyad Elkord;Eyad Elkord

  • Immune evasion in cancer: Mechanistic basis and therapeutic strategies

    Dass S. Vinay;Elizabeth P. Ryan;Graham Pawelec;Wamidh H. Talib

  • Significance of CD44 and CD24 as Cancer Stem Cell Markers: An Enduring Ambiguity

    Appalaraju Jaggupilli;Eyad Elkord;Eyad Elkord

  • Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting

    Belal Chaudhary;Eyad Elkord

  • Designing a broad-spectrum integrative approach for cancer prevention and treatment

    Keith I. Block;Charlotte Gyllenhaal;Leroy Lowe;Amedeo Amedei

  • Immune checkpoint inhibitors in cancer therapy: a focus on T‐regulatory cells

    Varun Sasidharan Nair;Eyad Elkord;Eyad Elkord

  • FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets.

    Reem Saleh;Eyad Elkord;Eyad Elkord

  • Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma

    Christy Ralph;Eyad Elkord;Deborah J. Burt;Jackie F. O'Dwyer

  • Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia

    Sai Daayana;Eyad Elkord;U Winters;M Pawlita

  • Acquired resistance to cancer immunotherapy: role of tumor-mediated immunosuppression

    Reem Saleh;Eyad Elkord;Eyad Elkord

  • Neuropilin 1: function and therapeutic potential in cancer.

    Belal Chaudhary;Yazan S. Khaled;Yazan S. Khaled;Basil J. Ammori;Basil J. Ammori;Eyad Elkord;Eyad Elkord;Eyad Elkord

  • Myeloid-derived suppressor cells in cancer: recent progress and prospects

    Yazan S Khaled;Basil J Ammori;Eyad Elkord

  • Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival

    Richard W Griffiths;Eyad Elkord;David E Gilham;Vijay A C Ramani

  • Immune checkpoints in the tumor microenvironment.

    Salman M Toor;Varun Sasidharan Nair;Julie Decock;Eyad Elkord;Eyad Elkord

  • Human monocyte isolation methods influence cytokine production from in vitro generated dendritic cells.

    Eyad Elkord;Paul E. Williams;Howard Kynaston;Anthony W. Rowbottom

  • Treg-mediated acquired resistance to immune checkpoint inhibitors.

    Reem Saleh;Eyad Elkord

  • Single-Cell Transcriptome Analysis Highlights a Role for Neutrophils and Inflammatory Macrophages in the Pathogenesis of Severe COVID-19.

    Hibah Shaath;Radhakrishnan Vishnubalaji;Eyad Elkord;Nehad M. Alajez

  • T cell responses and therapies against SARS-CoV-2 infection

    Salman M Toor;Reem Saleh;Varun Sasidharan Nair;Rowaida Z Taha

  • Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells.

    Varun Sasidharan Nair;Salman M. Toor;Bassam R. Ali;Eyad Elkord

  • Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients.

    Yazan S. Khaled;Basil J. Ammori;Eyad Elkord

  • T regulatory cells in cancer: recent advances and therapeutic potential

    Eyad Elkord;Erik M Alcantar-Orozco;Simon J Dovedi;Dat Q Tran

Frequent Co-Authors

Robert E. Hawkins
Robert E. Hawkins University of Manchester
Peter L. Stern
Peter L. Stern University of Manchester
Jan W. Drijfhout
Jan W. Drijfhout Leiden University Medical Center
Ranad Shaheen
Ranad Shaheen King Faisal Specialist Hospital & Research Centre
Maria Rosa Ciriolo
Maria Rosa Ciriolo University of Rome Tor Vergata
William G. Helferich
William G. Helferich University of Illinois at Urbana-Champaign
Katia Aquilano
Katia Aquilano University of Rome Tor Vergata
Graham Pawelec
Graham Pawelec University of Tübingen
Alexandros G. Georgakilas
Alexandros G. Georgakilas National Technical University of Athens
Shahab Uddin
Shahab Uddin Hamad Medical Corporation

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those studying Immunology in the USA, exploring related healthcare degrees can significantly broaden career opportunities. Many aspiring healthcare professionals consider accelerated pathways like the accelerated RN to NP programs to quickly transition into advanced nursing roles. These programs offer a streamlined approach for registered nurses seeking nurse practitioner qualifications without spending extra years in school.

For individuals without a nursing background interested in entering the field, online options such as online RN programs for non nurses provide accessible pathways. These programs help non-nurses gain foundational nursing skills to build careers in healthcare with flexibility.

If you are aiming to obtain a Bachelor of Science in Nursing quickly, investigating the easiest ABSN program to get into may be beneficial. These programs offer entry pathways with less competitive admission requirements, helping prospective nurses advance faster.

For advanced practice roles, acquiring an acute care nurse practitioner certification is essential for those focused on critical care specialties. This certification can unlock opportunities in hospital and specialized clinical settings, complementing immunology expertise.

Best Scientists Citing Eyad Elkord

Trending Scientists

Recently Published Articles